Gregory Larosa

Biography

Gregory LaRosa, PhD, is Vice President, and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit. Dr. LaRosa oversees all aspects of the Rare Disease Research Unit operations, including setting portfolio strategies, overseeing project progression, and working closely with the Business Unit colleagues. Dr. LaRosa received his PhD from Harvard University (Division of Medical Sciences) in Molecular, Cellular, and Developmental Biology. He has over 23 years of experience in rare disease and inflammation drug discovery and development. He worked to discover and begin the development of novel anti-inflammatory, peripherally acting, compounds that target alpha-7, and demonstrated efficacy in animal models of inflammatory and allergic disease. Additionally, Dr. LaRosa ran a collaboration with Medimmune on the discovery and characterization of mAbs to HMGB1, a novel target for the treatment of very severe life-threatening inflammation.

Research Interest

Inflammation drug discovery projects targeting chemokine receptors and kinases.